U.S. markets closed
  • S&P 500

    3,825.33
    +39.95 (+1.06%)
     
  • Dow 30

    31,097.26
    +321.83 (+1.05%)
     
  • Nasdaq

    11,127.84
    +99.11 (+0.90%)
     
  • Russell 2000

    1,727.76
    +19.77 (+1.16%)
     
  • Crude Oil

    108.46
    +2.70 (+2.55%)
     
  • Gold

    1,812.90
    +5.60 (+0.31%)
     
  • Silver

    19.77
    -0.51 (-2.50%)
     
  • EUR/USD

    1.0426
    -0.0057 (-0.54%)
     
  • 10-Yr Bond

    2.8890
    -0.0830 (-2.79%)
     
  • GBP/USD

    1.2103
    -0.0072 (-0.59%)
     
  • USD/JPY

    135.1750
    -0.5530 (-0.41%)
     
  • BTC-USD

    19,270.94
    -236.96 (-1.21%)
     
  • CMC Crypto 200

    420.84
    +0.70 (+0.17%)
     
  • FTSE 100

    7,168.65
    -0.63 (-0.01%)
     
  • Nikkei 225

    25,935.62
    -457.42 (-1.73%)
     

Marinus Pharmaceuticals to Present at Upcoming Medical and Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

RADNOR, Pa., May 18, 2022--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will participate in the following investor and medical conferences in May and June:

Citi Biotech Virtual Co-Panel Day
May 18 at 3:30 p.m. ET.
This presentation will be closed to conference participants only.

H.C. Wainwright Global Investment Conference
Available on demand starting May 24 at 7:00 a.m. ET.
Webcast Link: https://journey.ct.events/view/f447a79f-2d56-40f1-9924-e6b53707d9c1

Jefferies Global Healthcare Conference
June 9 at 3:30 p.m. ET in New York, N.Y.
Webcast Link: https://wsw.com/webcast/jeff240/mrns/1869600

16th EILAT Conference on New Antiepileptic Drugs and Devices
May 22 – 25 in Madrid, Spain
This event is closed to conference participants only.

Epilepsy Foundation Pipeline Conference
June 6 at 6:20 p.m. ET / 3:20 p.m. PT in Santa Clara, Calif.
This presentation will be closed to conference participants only.

About Marinus Pharmaceuticals
Marinus is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders. Ganaxolone is a neuroactive steroid GABAA receptor modulator that acts on a well-characterized target in the brain known to have anti-seizure effects. It is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings. For more information visit www.marinuspharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005448/en/

Contacts

Sasha Damouni Ellis
Vice President, Corporate Affairs & Investor Relations
Marinus Pharmaceuticals, Inc.
484-253-6792
sdamouni@marinuspharma.com